Immunotherapy has emerged as a significant therapeutic option in triple-negative breast carcinoma (TNBC), including low-grade variants, due to the immunogenic nature of this subtype and the presence of tumor-infiltrating lymphocytes and PD-L1 expression [173,174]. Here, CD274 is linked to triple-negative breast carcinoma.